Comparing Treatments After Surgery for Womb Lining Cancer
Compares chemotherapy with radiation, and two radiation types, in women with endometrial cancer.
Plain-language title generated from the registry record
Registry title: PErsonalized TReatment for Endometrial Carcinoma
Key facts
- Where
- Helsinki, FinlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT05655260, who can take part
Where in Finland
- Helsinki University HospitalHelsinki, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Helsinki
- Trial code
- NCT05655260
- Record updated
- 6 December 2024
- Original description
The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare:Read full original descriptionShow less
PErsonalized TReatment for Endometrial Carcinoma
The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare:
* Chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas. * Vaginal brachytherapy vs. whole pelvic radiotherapy in the MMR-D molecular subgroup. * Vaginal brachytherapy vs. whole pelvic radiotherapy in the NSMP molecular subgroup.
Inclusion: Age 18 to 100 years; WHO performance status 0 to 2; Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma.
Exclusion: Previous pelvic radiotherapy; An interval of >30 days between surgery and start of chemotherapy or >8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval); A history of malignancy within 5 years; Age <18 years or >100 years; WHO performance status >2; Uterine sarcoma.